Fifteen Japanese corporations will deliver short presentations explaining their strategic and investment priorities to an audience of high-profile medtech startups and others at a Reverse Pitch event organized by the US-Japan Healthcare Connection as part of the Medtech Innovator (MTI) Annual Innovator Summit. The Reverse Pitch Event and MTI Summit will be held at the Computer History Museum in Mountain View, CA on June 15, 2023.
The Reverse Pitch program is designed to introduce Japanese companies that are highly interested in the healthcare/medtech industry as potential strategic partners and/or investors in early-stage medtech ventures. After the presentations, the presenting companies will be available to meet individually with Summit attendees to discuss areas of mutual interest. Companies that will be presenting are:
The tentative schedule for this event is 2:30-4:30 p.m., and attendance is limited to companies that have been pre-approved to participate. If you are interested in attending, please contact us at email@example.com.
2:00 P.M. – 2:30 P.M.
2:30 P.M. – 4:30 P.M.
PRIVATE EARLY STAGE AND PRIVATE COMPANY PRESENTATIONS
Yusuke Kogata has 20 years of experience in medtech and pharmaceutical industries, mostly as business development and sales/marketing. He joined ReCor in April, 2023 as Senior Director, Planning and Business Development, supporting the development of business strategy on a global basis, working cross functionally with the ReCor and Otsuka leadership teams, and also supporting partnering strategies with industry partners. Prior to ReCor, he led entire Otsuka RDN business as Otsuka RDN Project Leader at Otsuka Medical Devices in Tokyo, including conducting clinical studies, and developing regulatory/marketing strategies in Japan/Asia as well as global strategies with US/EU team as a global team. Prior to that, his responsibility as Senior Manager at Business Development at Otsuka Holdings was to seek investment opportunities in mainly medtech field, where he picked up ReCor and its uRDN and raised the opportunity to the management, which ended up with approval of investment and eventually acquisition of ReCor in 2018.
About Otsuka Medical Devices Co., Ltd.
Otsuka Medical Devices Co., Ltd. focuses on the global development and commercialization of medical care products including endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).
About ReCor Medical, Inc.
ReCor Medical, headquartered in Palo Alto, CA, a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. ReCor has pioneered the use of the Paradise Ultrasound Renal Denervation (uRDN) System for the treatment of hypertension. The Paradise System is an investigational device in the United States and Japan and bears the CE mark in the EU. ReCor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise System in patients with mild-to-moderate and resistant hypertension, and has submitted an application for PMA approval in the United States with the U.S. FDA. In addition, ReCor has begun the Global Paradise System (“GPS”) Registry in the EU with plans to expand globally.
Hirobumi Watanabe is a mechanical engineer who has received a Ph.D. in Neuroscience from NYU. With expertise as both an engineer and scientist, he has made significant contributions to the fields of micro-fabrication, electrophysiology, neuro-intervention, and otolaryngology. Presently, he serves as the leader of Advanced Technology Research at Asahi Intecc USA, situated in Irvine, CA. In this capacity, he conducts a range of research projects from different angles, focusing on stroke and endovascular electrophysiology. Prior to joining Asahi Intecc, he enjoyed valuable experience working at prominent startup companies in the field of brain-machine interfaces, namely Neuralink and Kernel. These companies are recognized for their innovative contributions in this area.
Asahi Intecc Co., Ltd. is a leading global company at the forefront of medical device innovation, specializing in the development and manufacturing of minimally invasive medical devices. With a strong commitment to improving patient outcomes and advancing medical technology, Asahi Intecc has established itself as a renowned company with a global presence.
Asahi Intecc has played a pivotal role in revolutionizing the treatment of chronic total occlusion (CTO) through the development of high-quality guide wires. CTO is a challenging condition where blood vessels are completely blocked, requiring precise and effective intervention. With their state-of-the-art guide wires, Asahi Intecc has empowered physicians to navigate complex anatomy, cross lesions, and deliver therapeutic agents with unparalleled precision and reliability.
Building on this success, Asahi Intecc has expanded its portfolio beyond interventional cardiology, now encompassing neurology and peripheral vascular intervention as well. By combining cutting-edge engineering expertise with a deep understanding of clinical needs, Asahi Intecc continuously strives to deliver groundbreaking solutions that address the challenges faced by healthcare professionals and patients worldwide.
Leveraging their metallurgical and polymer engineering capabilities, Asahi Intecc has developed a diverse range of high-quality medical devices. This expansion includes not only guide wires but also catheters and other advanced tools designed to facilitate precise and minimally invasive procedures. By broadening their portfolio, Asahi Intecc aims to provide comprehensive solutions to healthcare professionals, empowering them to deliver optimal patient care in different medical domains.
With a strong global presence, Asahi Intecc operates subsidiaries and offices in key markets around the world, including the United States, Europe, Asia, and Latin America. This extensive network enables the company to provide timely support and solutions to healthcare providers.
Dr. Morimoto leads multiple global teams to generate new businesses in the life science industry through M&A, venture investment, and organic R&D. In addition to capital, his teams provide hands-on support to its portfolio companies with precision manufacturing, global supply chain management, business development, and fund raising. Yuichiro is on the board of many of the companies Enplas has invested in.
Prior to joining Enplas, Yuichiro worked for McKinsey & Co. for 10 years consulting to global clients in medical device and pharmaceutical industries. Yuichiro holds a Ph. D. in nuclear engineering from the University of Tokyo.
Founded in 1962, Enplas is one of the world’s leading independent manufacturers of high-performance custom injection-molded devices and components for various industries. Enplas’s Life Science Company offers high-performing, high-precision custom plastic devices and components to market-leading customers and growing start-ups. Our mission is to improve quality of life (of all living beings) by delivering innovative engineering and manufacturing solutions.
Enplas develops and manufactures custom consumables and devices such as reagent-loaded diagnostic cartridges, manifolds, microfluidics, fluid seals, and more. Applications include Next Generation Sequencing, digital PCR, molecular Point-of-Care Testing, single cell analysis, cell handing, Organ-on-a-Chip, biopharma manufacturing, and other In-Vitro Diagnostics and Research-Use-Only applications.
Enplas offers unique technological capabilities in microfluidics injection molding, lyophilization, liquid reagent handling and packaging, cartridge mass manufacturing, and biology on (plastic) chips. Enplas provides end-to-end services to its customers, including design development and Design-for-Manufacturability, rapid prototyping, and mass production launch with ISO13485 certified sites in the U.S. and Japan.
Enplas’ life science customers range from growing startups at the prototyping stage to multi-billion dollar global medical and diagnostic device OEMs with large volume production supplying the market. Enplas collaborates with start-up companies offering technical expertise. We wish to create new markets and products with companies focused on the molecular PoCT, liquid biopsy, single cell analysis and Organ-on-a-Chip markets, leading the market with innovation together.
As Sr. Marketing Manager at Fujikura America, Joshua Magnuson is responsible for leveraging the technical expertise and market leadership of Fujikura in electronics miniaturization, fiber optics, sensor technology and CMOS for a diverse number of industries including medical device and medical diagnostic fields. Prior to joining Fujikura, Joshua has worked as both a product marketer and product development scientist in a diverse array of fields including medical device, medical diagnostics, and biotechnology. He has worked for Abbott Laboratories and Bio-Techne, among others, as well helping to found two startup companies in the Minneapolis-Saint Paul area. Joshua has an MBA from the Carlson School of Management at the University of Minnesota and a B.S.-Biology/B.A.-History from Bethel University. He is an Affiliate Member and Board Member of the Medical Industry Leadership Institute at the University of Minnesota.
Fujikura is a 138 year-old company based in Tokyo, Japan. A global leader in fiber optics and electric wiring, Fujikura serves a broad range of industries including Telecommunications, Automotive, Consumer electronics and Medical Devices. Within the medical device space, Fujikura is focused on electronics miniaturization for wearable technology, fiber optics for a variety of medical imaging applications and CMOS camera modules for single-use disposable endoscopy. Our CMOS camera modules are single use disposable to lower the risk of infection and the cost of reprocessing while also being highly adaptable to a variety of designs and lighting options, allowing them to be used in a number of different specialties.
Rubal Bedi is the Global Head, Vice-President of Corporate Venture Capital at HOYA Corporation, a $45 billion multinational company, focusing on medical device, diagnostic, and digital health investments. Currently, Rubal represents HOYA on the boards of Centricity, Cryosa, and Eye-Q. Before joining HOYA, Rubal was a Director at Ascension Ventures, a hospital-based venture capital fund, where he led investments in BardyDx (acquired) and Neuronetics (IPO). Rubal previously led business development and strategy within Medtronic’s $1.6 billion Aortic and Peripheral Vascular division. While he was at Medtronic, Rubal led investments in Shockwave Medical (IPO), Lyra Therapeutics (IPO), and Arsenal Medical. Prior to his tenure at Medtronic, Rubal worked at PTV Healthcare Capital, a late-stage venture and growth equity firm. During his time there, Rubal worked with the entrepreneur in residence in the formation of Apollo Endosurgery (IPO). He received an MBA from the McCombs School of Business at the University of Texas at Austin and a BA in Economics from the University of California at Irvine. Outside of work, he enjoys spending time with his family, rooting for his Bay Area sports teams, and traveling internationally.
HOYA Corp is a diversified, multinational company and supplier of innovative and indispensable high-tech and healthcare products. HOYA is active in two core business segments: The Life Care segment and Information Technology segment. The Life Care segment encompasses health care areas such as eyeglass lenses and the operation of contact lens retail stores, intraocular lenses, as well as medical endoscopes, surgical equipment and artificial bones and implants. Examples of therapeutic areas of interest includes: presbyopia, myopia, glaucoma, metabolic disease, BPH, airway disease, etc. Information Technology segment focuses on electronics products for the semiconductor industry and LCD panels, glass disks for HDDs and optical lenses for digital cameras and smartphones.
Aki has been President and CEO of LINK-J since its foundation in 2016. Earlier in his career, he served as Deputy Director of METI (GOJ), Manager of Boston Consulting Group in Tokyo, Vice President/General Manager of Johnson and Johnson Japan, President of Biotronik Japan and President of Haemonetics Japan. Aki holds an MBA from Columbia University and a BS (Physics) from University of Tokyo. Aki also serves as specially appointed Professor of Tohoku University and life science related committee member of MHLW (GOJ), METI (GOJ), AMED(GOJ), Kobe City, Sapporo City, etc.
LINK-J (the general incorporated association Life Science Innovation Network Japan) is the largest innovation ecosystem builder in Japanese life science area. It covers a wide range of life science such as drug discovery/regenerative medicine/medical device, prevention, and longevity of life. With its about 700 members LINK-J has hosted more than 800 symposium, seminars, incubation/acceleration programs and matching/pitch events in 2022. Its facilities are in 15 buildings in a very business center of Tokyo (only 10 minutes’ walk from Tokyo Station) as well as in Osaka (west Japan) and so on.
Satoshi Iwata is in charge of Medtech business development based in the Bay Area. He is instrumental in creating business partnerships with North American and European Medtech companies to develop new businesses in the Japanese and Asian markets. Satoshi mainly focuses on cutting-edge Medtechs for acute care hospitals and other therapeutic and diagnostic solutions such as devices for OR/ICU, surgical, and robotics. Additionally, he is responsible for the BD projects of SaMD and Medtech digital transformation. Before his current role, he was engaged in sales and marketing in the Japanese Medtech field for around ten years.
Mitsubishi Corporation (Americas) is a wholly owned subsidiary of Mitsubishi Corporation, a global integrated business enterprise with 10 business groups that operate across virtually every industry. These include natural gas, industrial materials, petroleum & chemicals, mineral resources, industrial infrastructure, automotive & mobility, food industry, consumer industry, power solution, and urban development.
Mitsubishi Corporation operates a wide range of businesses, including medical device, supply chain, digital health, healthcare service, elderly care, living care, and so on in the healthcare space.
In the Medtech business, Mitsubishi Corporation focuses on general surgery, laparoscopic surgery, orthopedic, OB/GYN, urology, GI, ENT, respiratory/anesthesia, radiology, and cardiology. Mitsubishi Corporation has long-term partnership agreements with U.S. and European Medtech startups in the Japanese market to facilitate importing, sales and marketing, regulatory filing, quality management, etc.
Yukari Tanimoto Guevara is the Director of ICT (Information, Communication and Technology) at Mitsui Chemicals America, Inc, a diversified chemicals company with offices in San Jose and Headquarters in New York. She received her Bachelor of Arts at UC Berkeley.
Her tenure with Mitsui Chemicals started in February 2022 and prior to that, she was a Senior Market Development Manager at Kaneka Corporation overseeing thermal management materials to major Tech companies and Bio-surfactant for Personal Care Industries. Prior to that, she worked in New Business Development in various advanced tech sectors and also some projects supplying IV Bags for large Government contracts.
Mitsui Chemicals main business sectors span Mobility, Basic and Green Materials, Life and Healthcare and ICT. She is excited to meet with US-Japan Healthcare Connection Communities and StartUps to introduce Mitsui Chemicals InnoCell Product today.
Mitsui Chemicals’ roots can be traced back to 1912 when it began producing raw material for chemical fertilizers from coal gas byproducts, the first company in Japan to do so. This undertaking significantly contributed to increasing agricultural productivity, a major social issue at the time. Later, the company evolved its technology from coal chemicals to gas chemicals, and in 1958 it built Japan’s first petrochemical complex and so provided impetus to Japan’s industry. Today, the company boasts many world-class products with sales standing at over 1,600 billion yen and with over 160 companies in 30 countries. Its business portfolio includes Life＆Healthcare Solutions, Mobility Solutions, ICT Solutions, Basic & Green Materials.
Mitsui Chemicals will continue to contribute to solving social challenges with its state-of-the-art technology and by “Creating New Customer Value through Innovation”.
More information can be found at https://www.mitsuichem.com
Hiroyoshi Take, Ph.D. is responsible for tech-scouting, evaluating, structuring partnerships, and possible investment in digital health technologies.
Nitto Denko is a global company specializing in advanced materials and technologies, making significant strides in various industries including healthcare. With a rich history spanning over 100 years, Nitto Denko has continuously driven innovation and contributed to the betterment of society.
Nitto Denko is working in two important areas of healthcare: heart failure and mental health. These diseases affect millions of people worldwide, and Nitto Denko is committed to developing cutting-edge solutions to improve the quality of life for patients.
We have focused on developing a patch-type wearable device for diagnosis in the field of heart failure. Through extensive research and collaboration with medical experts, pilot sales are being conducted in Japan.
Furthermore, Nitto Denko recognizes the urgent need to address mental illness, which has a profound impact on individuals, families, and communities. Nitto Denko is developing a wearable device sensor that detects mental health conditions. The device is intended to be used, for example, for monitoring during counseling sessions.
Nitto Denko is committed to providing comprehensive solutions that address the unmet needs of patients suffering from heart failure and mental illness. We are looking for partners who together aim to make a positive difference in the lives of people around the world.
Toshio Fujimoto, MD. MBA. is the CEO of iPark Institute, Co. Ltd., which aims to develop innovation ecosystem of life science at Shonan Health Innovation Park (iPark) in Japan. Shonan iPark was opened in April 2018 as a part of Takeda Pharmaceutical and Dr. Fujimoto has led the initiative as General Manager since he joined Takeda in Dec 2017. In April 2023, iPark Institute was spun off to operate the business of science park.
Prior to joining Takeda, he worked at Eli Lilly Japan for over 10 years to oversee the whole R&D function as Vice President, Medicines Development Unit. Earlier in his career, he was a thoracic surgeon and worked in renowned hospitals in Japan, Germany, and the US.
He received his M.D. from Kyoto University and his M.B.A. from Kobe University.
iPark Institute Co., Ltd. was established in April 2023 to build and develop life science ecosystem in Japan. It succeeded its operation from Takeda Pharmaceutical, one of the biggest global pharmaceutical companies originated in Japan. Takeda has located its research center for drug discovery in Shonan since 2011, and transformed it into a hub for open innovation, called Shonan Health Innovation Park (iPark) which started its operation in 2018.
With a vision to bring innovative ideas to society, iPark has been engaging in several core activities to catalyze innovation, which are to provide high quality research service and facility, to attract diverse types of companies, to facilitate their interactions, to incubate startups, and to provide platforms for collaboration. As a result, more than 100 tenant and 60 membership companies (as of 04.2023), from early startups to big companies, are gathering at iPark. Majority of them are biopharmaceutical companies, while university offices, companies from food and cosmetic industries, MedTech companies, AI/Dx companies are also included. They are forming a big science community to share ideas and experiences daily, which leads to many collaborative research projects, newco generation, and businesses partnerships at iPark.
Takahito Ishikawa is a manager for Medical & Bio Products at Sumitomo Plastics America, a subsidiary of Sumitomo Bakelite. He has experiences in R&D and business development for medical devices as well as R&D for plastics. He is currently seeking innovative companies to collaborate with in the field of medical devices and bio products.
Sumitomo Bakelite offers chemical-based products including plastics, medical devices and bio products. In the medical device industry, our subsidiary, SB-KAWASUMI LABORATORIES is engaged in research, development, manufacturing and sales of medical devices for gastrointestinal endoscopic/endovascular treatment, surgical drainage, dialysis, blood sampling and transfusion in Japan and other countries. Our manufacturing sites provide quality products globally under a quality management system which meets each country’s strict pharmaceuticals and medical device standards. We seek the partners with whom we can collaborate in distribution in Japan or manufacturing to continuously contribute to the improvement of Quality of Life.
RDCA is a wholly owned subsidiary of Sysmex Corporation, focused on realizing preventive medicine and bringing new clinical applications from the US to the rest of the world via the Sysmex organization.
Kenjiro leads growth initiatives related to digital health and digital therapeutics. In that capacity, he is particularly eager to meet with early-stage companies developing innovative new digital diagnostic and therapeutic solutions.
Before joining Sysmex, he held a position at Omron Healthcare, where he led the global development of the remote patient monitoring system business. He received his bachelor’s degree in Environment and Information studies from Keio University and is now pursuing Master of Business Administration from Indiana University, Kelley business school.
Shrey is determined to uncover latent needs of patients to solve unmet needs in healthcare. A former program manager in Sysmex Japan, now focusing on digital health strategy in the Bay Area.
Bachelor of Engineering, Electronic Engineering, Hong Kong University of Science and Technology
Former Co-founder of Glaulens, a wearable soft contact lens with embedded circuit to detect changes in IOP (intraocular pressure) to avoid missed glaucoma diagnoses.
Sysmex corporation is a leading IVD company from Japan specializing in high throughput blood and urine testing. The digital healthcare section is based in the bay area in California.
We are interested in startups in the following areas.
Digital Health, Digital Medicine, Digital Therapeutics, Digital Biomarkers, Home Care
CNS diseases(e.g. Dementia), Cardiovascular diseases(e.g. HF, Stroke), Life style diseases(e.g. Hypertension)
KOL networks, Assist for regulatory approvals, clinical studies, and global market entries
Yosuke Matsubara is a Business Development and Licensing Manager at Teijin Pharma, a Tokyo-based company that operates in both pharmaceuticals and medical devices. With over 10 years of experience in drug development at Teijin Pharma, Yosuke’s expertise lies in clinical trials, negotiating with regulatory agencies for approval, and project management.
Yosuke is responsible for licensing-in both medical devices and drugs, focused on exploring potential collaborations and partnerships with startups in the medical device and drug spaces. Teijin Pharma’s medical device business is limited to home-use devices, and its businesses are limited to the Japanese market. Many of the company’s available products in Japan are from overseas, and licensing-in is an important activity.
Yosuke earned his Ph.D. degree in medical science before joining Teijin Pharma in 2008. Prior to joining Teijin Pharma’s medical device business in 2021, he gained extensive experience in drug development.
Teijin Pharma is a healthcare company focused on delivering innovative home-use medical devices and pharmaceuticals to the Japanese market. With a strong emphasis on patient support, we have established an extensive service network throughout Japan, enabling us to provide direct delivery, education, setup, and maintenance services for our medical devices in the comfort of patients’ homes. Our portfolio includes cutting-edge technologies in respiratory, orthopedic, metabolic, and other therapeutic areas. We are actively seeking to expand our medical device business, particularly in the area of psychiatric diseases like depression, ADHD, and PTSD. Additionally, we are interested in partnering with companies developing home-use treatment medical devices and monitoring devices for early detection of exacerbations to prevent readmissions. In the respiratory disease area, we have a leading market share in Japan for our home oxygen concentrator and CPAP devices, providing life-changing benefits to patients with COPD and sleep apnea. To ensure timely and efficient support for our patients, we have a call center that is available 24/7. Our highly trained and knowledgeable staff are always available to answer questions and provide assistance, helping to ensure that our patients receive the best possible care.
We have a strong track record in regulatory approvals with the Japanese agency, and our products are reimbursed in Japan. We are always interested in exploring partnerships with innovative companies in the healthcare space, and we can help distribute your device in Japan through our established channels. As a core group company of Teijin, we have access to extensive resources and expertise in research and development, allowing us to continue to drive innovation in the healthcare industry and shape the future of patient care. We also have a venture capital fund in the US, focused on early-stage startup investments for companies seeking investment opportunities.
Yushin Yazaki is currently the Director of Venture Arm at Terumo Corporation. Previously, he held the position of Global Products Manager in the same company. Yushin received his Master’s degree from Hitotsubashi ICS (Hitotsubashi University Business School) and his PhD in Materials Science from Waseda University.
Terumo has three companies; Cardiac and Vascular Company, Blood and Cell Technologies Company, and Medical Care Solutions Company.
The businesses of the Cardiac and Vascular Company involves the heart, lung, and brain, and treatment of blood vessel diseases throughout the body. The company provides interventional devices, oxygenators and heart-lung machines, and surgical grafts and stent grafts globally.
Blood and Cell Technologies Company provides collection and processing sets and other supplies for efficient blood processing. Additionally, the company provides devices that use centrifugation and separation technology to collect or remove specific blood components, enabling a variety of blood treatment solutions. In the fields of cell and gene therapy, the company provides research institutions and pharmaceutical companies with instruments and services that enable high-quality, large-scale production of cell products to support the creation of new therapies.
Different from above two Companies, Medical Care Solutions Company is doing the business broadly, but mainly focusing Japanese market. The company offers a variety of expertise to address the needs of those in medical care settings, including medical safety, in-facility infection prevention, and cost control. These include advanced infusion system, peritoneal dialysis, infection prevention and environmental control, preoperative and oncological products. Chronic diseases are also their focus. The company provides the products in the areas of diabetes care, heart failure care, and vital sign management in hospital and home settings. Additionally, the company offers solutions to pharmaceutical companies globally by proposing new drug delivery devices. They leverage its material technology optimized for the characteristics of each drug and utilizes advanced manufacturing technology to design and produce drug-device combination products. Through alliances with pharmaceutical companies, they provide a total solution from clinical trial drug manufacture to full commercialization.
After working as an MR at Dainippon Sumitomo Pharma, Mr. Masaru Fukunaga worked as a consultant at Eliment HRC, a headhunting company specializing in the medical industry (life sciences), and contributed to the promotion of the medical device business as a division manager.
He was involved in various projects such as executive search at a UK-based consulting firm specializing in life sciences, and met more than 500 medical business talents per year. He has knowledge of medical business from upstream to downstream, from drug discovery to regulatory submission and launch, and has relationships with various medical business personnel and pharmaceutical/medical device companies.
Later, he established xCARE, Inc. to solve problems and promote innovation in the medical business.
xCARE (Cross Care) provides hands-on support and recruitment support in the field of medical business (pharmaceuticals, MedTech, regenerative medicine). There are more than 150 experts with various skills who are registered on xCARE’s human resources platform. xCARE’s hand’s on support enables to cover a wide range of tasks, by forming a team with such experts, in the area of product development and commercialization including regulatory affairs, clinical trials, and quality systems. This service is greatly appreciated by the companies from many countries (particularly start-ups) that are not ready to hire personnel but need medium/short-term resources to develop the business in Japan. xCARE also supports Japanese companies to develop the business outside Japan collaborating with the experts in each country. Please contact us for more information.